Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announces that it has been authorized by Health ...

Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to ...

South Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...

The treatment – SteQeyma -- is an ustekinumab biosimilar treatment for multiple chronic inflammatory diseases. According to Celltrion, it was released in France, following its launch in Italy and ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma ® (CT-P47), a biosimilar referencing RoActemra ® (tocilizumab). Avtozma ® has been ...

Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma ...

STEQEYMA is indicated for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA) in adult and pediatric patients, as well as Crohn's disease (CD) and ulcerative colitis (UC) in adult ...